UK's NICE recommends approval for Servier's Voranigo

Independent French pharma major Servier announced that the UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Voranigo (vorasidenib), a once-daily oral targeted therapy indicated for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.

Based on NICE’s final draft guidance published on March 31, recommending vorasidenib, immediate access is available to eligible patients across England and Wales via interim funding through the cancer drugs fund (CDF).